Product Images Jardiance

This appears to be a list of medication names with their recommended dosage and frequency. However, there is also a section at the bottom with a mix of letters and numbers that is not clear enough to determine what it represents.*

This is a chart showing the mean change from baseline in HbA1C (%) for patients taking placebo, empagliflozin 10mg, and empagliflozin 25mg. The chart is divided into different time periods (baseline, 6 weeks, 12 weeks, 18 weeks, and 24 weeks) and indicates that empagliflozin resulted in a greater reduction in HbA1C compared to placebo. The results are adjusted for baseline HbA1C, geographical region, and oGFR.*

This is a clinical data table comparing the mean change from baseline HbA1c levels of Glimepiride + Metformin and Empagliflozin 25mg + Metformin in a study consisting of 700 and 693 individuals, respectively. The table shows data for various weeks up to 52 weeks. The mean change from baseline is adjusted for baseline HbA1c, geographic region and eGFR at baseline.*

This table appears to show the percentage of patients experiencing an event (not specified) over time in a study comparing a placebo group to a group taking Empaglifiozin, with the number of subjects at risk for each time point listed. The table has no header or context, so it is not possible to provide a more specific description of the study or results.*

This appears to be a table or graph displaying the incidence of a function, possibly related to Empaglifiozin 10 mg compared to a placebo group, with various p-value and HR (hazard ratio) values. The chart also includes a list of patients at risk and days since randomization.*

This text appears to be a statistical table evaluating the effectiveness of a medication called Empagifiozin 10mg versus a placebo for people with diabetes and different baseline health conditions, including heart failure physiology and GFR at baseline. It also includes statistics on the participants' demographics, such as sex, race, and BMI. The table measures the Hazard ratio, which assesses the risk of an event (such as death or hospitalization) occurring in the treatment group compared to the control group.*

This appears to be a table or graph displaying data for a comparison between placebo and a medication called Empagliflozin 10 mg in a study involving 2991 and 2997 participants, respectively. The data seems to show the mean number of events observed, and indicates that the medication had a statistically significant effect compared to placebo based on a hazard ratio, confidence intervals, and p-value. The table also shows the number of patients at risk and days since randomization for both groups.*

This text appears to be a statistical table with various categories, subgroups, and numerical values related to a medical study. It includes information about a medication called Empagifiozin 10mg, compared to a placebo, for the treatment of diabetes. The table also contains data on demographics, baseline health conditions, and medication use of the participants.*

This is a medication description for product number 9842-0, which contains 90 tablets of Empagliflozin (25mg each). The text also includes some seemingly random characters that are not recognizable.*